glucagon receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-29. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Ibogaine biosynthesis begins with tryptophan undergoing enzymatic decarboxylation by tryptophan decarboxylase (TDC) to form tryptamine. Secologanin, an iridoid synthesized from isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), is reacted with tryptamine to make strictosidine. A glycosidic bond cleavage of strictosidine by strictosidine β-deglucosidase (SGD) produces a lactol. The lactol opens and produces an aldehyde, then condenses to form an iminium. Through isomerization and reduction by geissoschizine synthase 1 (GS1), 19E-geissoschizine is yielded. The indole is oxidized, and the molecule undergoes an intramolecular Mannich reaction and Grob fragmentation to form preakuammicine. Preakuammicine is highly unstable and therefore reduced to stemmadenine by oxidation-reduction reactions (REDOX 1 and REDOX 2). Stemmadine is acylated by stemmadine Ο-acetyltransferase (SAT) to yield stemmadine acetate. Through oxidation by precondylocarpine acetate synthase (PAS) and reduction by dihydroprecondylocarpine acetate synthase (DPAS), an enamine intermediate is formed. The intermediate undergoes fragmentation to produce an iminium that tautomerizes to yield dehydrosecodine. Coronaridine synthase (CorS) catalyzes the isomerization of dehydrosecodine, and an unusual cycloaddition is completed. DPAS and NADPH reduce the iminium to form (-)-coronaridine. There are two pathways (-)-coronaridine can take to become (-)-ibogaine.
== Pharmacokinetics == After oral ingestion, glycyrrhizin is hydrolysed to 18β-glycyrrhetinic acid (enoxolone) by intestinal bacteria. After absorption from the gut, 18β-glycyrrhetinic acid is metabolised to 3β-monoglucuronyl-18β-glycyrrhetinic acid in the liver. This metabolite circulates in the bloodstream. Consequently, its oral bioavailability is poor. Most of it is eliminated by bile and only a minor part (0.31–0.67%) by urine. After oral ingestion of 600 mg of glycyrrhizin the metabolite appeared in urine after 1.5 to 14 hours. Maximal concentrations (0.49 to 2.69 mg/L) were achieved after 1.5 to 39 hours and metabolite can be detected in the urine after 2 to 4 days.
== Education == Burnham earned her Ph.D. in medical sciences at the University of Alberta in 2007. Later, she pursued fellowship training in clinical microbiology at Washington University in St. Louis, which she completed in 2009.
=== Immunocompetence === Evidence suggests that in many animal species, secondary sexual traits reflect male immunocompetence, the ability of an individual's immune system to resist and control pathogens or parasites. A study found that a single parasite-like immunological challenge, created via a nylon monofilament implant in the beetle, significantly reduced the sexual attractiveness and locomotor activity of males, but did not negatively affect their survival. When the inserts were removed, the majority of the males showed greater encapsulation responses of the implant, though some of the males seemed to have already chosen a terminal reproductive investment strategy. And thus, the majority of males invest in their immune system after the first challenge. A second immune challenge increased their attractiveness, but was found to significantly reduce locomotor activity of the males and increase their mortality. This represents a trade-off between pheromone production and energy required for activities such as immune system recovery and locomotor activity. When there was a third challenge implantation in the same males, there was a lower encapsulation rate of the nylon implants in more attractive males than the less attractive, showing that the males made no attempts to boost their immune system. The results suggest that males that become sexually attractive after the second immune challenge have a trade-off, where they sacrifice locomotor activity and do not energetically invest in immune system recovery.
== Discovery == GnIH was discovered in 2000. It is an RFamide peptide that significantly reduced luteinizing hormone release in Coturnix Japonica (Japanese quail). This peptide emerged as the first tropic hormone known to inhibit gonadotropin secretion in the hypothalamic-pituitary-gonadal axis of vertebrates. Subsequent research identified GnIH peptide homologs in variety of mammals, including humans.
Sources: en.wikipedia.org
Dom Pothier died at the old priory of Conques, Belgium in 1923; the Bishop of Luxembourg and six prelates attended his funeral at Clervaux abbey, Luxembourg (his remains later were transferred to Saint-Wandrille in 1962). The exiled community of St Wandrille's Abbey, under Dom Pothier as Abbot, founded in 1912 a new priory in Canada, Saint Benedict Abbey, Quebec, which later became independent within the Solesmes Congregation.
The Monovalent Cation:Proton Antiporter-2 (CPA2) Family (TC# 2.A.37) is a moderately large family of transporters belonging to the CPA superfamily. Members of the CPA2 family have been found in bacteria, archaea and eukaryotes. The proteins of the CPA2 family consist of between 333 and 900 amino acyl residues and exhibit 10-14 transmembrane α-helical spanners (TMSs).
== Adverse effects == There are limited amounts of research available on the effects of 3-CMC. The effects are likely comparable to those of other cathinones of which it is known exposure can result in symptoms such as tachycardia, hypertension, and episodes of psychosis. Users also report other side effects including an increase in body temperature, sweating, anxiety, and dry mouth.
Pilonidal cysts can recur, and do so more frequently if the surgical wound is sutured in the midline, as opposed to away from the midline, which obliterates the natal cleft and removes the focus of shearing stress. An incision lateral to the intergluteal cleft is therefore preferred, especially given the poor healing of midline incisions in this region. Minimally invasive techniques with no wound and rapid return to full activities have been reported but await double-blind randomized trials. Another technique is to treat the pilonidal sinus with fibrin glue. This technique is of unclear benefit as of 2017 due to insufficient research. The evidence for any treatment is of low quality, and care must be taken not to overinterpret any study in this field. Since the 2010s, several minimally invasive techniques have been developed to minimize the impact of surgery on patients and achieve less pain and shorter recovery times. In some cases, the wounds are left open after surgery to heal naturally instead of being closed with stitches. There are a lot of different dressings and topical agents (creams or lotions) that are available to help these open wounds heal. A 2022 systematic review brought together evidence from 11 studies that compared dressings and topical agents for treating open wounds after surgical treatment for pilonidal sinus of the buttocks.
Sources: en.wikipedia.org
Lectins are carbohydrate-binding proteins that are highly specific for sugar groups that are part of sugars and other molecules. Lectins can recognize specific types of sugar moieties and play a role in the recognization of carbohydrates and glycosylated proteins. This recognition is used within organisms to mediate binding between specific cell types, to recognize chemical messages, and to recognize foreign cells: for example, the human lectin CLEC11A conveys a signal for bone growth. Lectins are also used by pathogens such as bacteria, viruses, and fungi to recognize and tightly attach to their host cells. Because lectin binds sugar moieties, it can "glue" together entities that have similar sugar moieties. Many cells have specific types of surface glycans; when a lectin is added, they become glued together or agglutinated. Glycoconjugates and polysaccharides that share similar moieties can likewise be glued together, making them precipitate out of a solution. By using the correct lectin, one can separate out entities that have a certain sugar moiety. This is useful for the determination of blood type and separating cells by type. Because a lectin molecule can only bind a handful of sugar groups, it can be disabled by an excess of the sugar group that it recognizes. Lectins are found in all domains and kingdoms of life, from the prokaryotes to the eukaryotes, from the plants to the animals.
Formic acid, which has a pungent, penetrating odor, is found naturally in insects, weeds, fruits and vegetables, and forest emissions. It appears in most ants and in stingless bees of the genus Oxytrigona. Wood ants from the genus Formica can spray formic acid on their prey or to defend the nest. The puss moth caterpillar (Cerura vinula) sprays it as well when threatened by predators. It is also found in the trichomes of stinging nettle (Urtica dioica). Apart from that, this acid is incorporated in many fruits such as pineapple (0.21 mg per 100 g), apple (2 mg per 100 g) and kiwi (1 mg per 100 g), and in many vegetables, namely onion (45 mg per 100 g), eggplant (1.34 mg per 100 g), and in extremely low concentrations, cucumber (0.11 mg per 100 g). Formic acid is a naturally occurring component of the atmosphere primarily due to forest emissions.
Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for vitamins and minerals, PRIs for the European Union (same concept as RDAs), followed by what three government organizations deem to be the safe upper intake. RDAs are set higher than EARs to cover people with higher-than-average needs. Adequate Intakes (AIs) are set when there is insufficient information to establish EARs and RDAs. Countries establish tolerable upper intake levels, also referred to as upper limits (ULs), based on amounts that cause adverse effects. Governments are slow to revise information of this nature. For the U.S. values, except calcium and vitamin D, all data date from 1997 to 2004.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.